A#2585 PsABIOnd observ cohort study of IL23 (GUS) or IL17i 6 mo interim results of 686 pts PROs: PsAID-12 High Rx persistence at 6mo -94% on both Rx Comparable improvement in PsAID-12 - best results skin, discomfort 1/2 with clinically meaningful improvement #ACR24 @RheumNow https://t.co/TM1jwTRR7C

• https://x.com/ericdeinmd/status/1858589439746068566/photo/1
• https://x.com/ericdeinmd/status/1858589439746068566/photo/1
• https://x.com/ericdeinmd/status/1858589439746068566/photo/1

A#2586 EBIO study - secukinumab on entheseal bx in PsA. Compare b/l to 3+ mo on SEC Biopsy: change of entheseal cell composition on IL-17A Rx - decr Il-17A producing cells in responding pts Spatial transcriptomics - colocalizarjon of ILC2, CD200+ fibroblasts @RheumNow #ACR24 https://t.co/kMiqpBRxuE

• https://x.com/ericdeinmd/status/1858593064912028040/photo/1

Walsh et al. Direct mailing of PEST questionnaire to psoriasis patients. 13% PEST+, 4% seen by rheum (to date). 75% deemed appropriate for rheum to see - breakdown in picture. @RheumNow #ACR24 Abstr#2635 https://t.co/vlGJ977SV7 https://t.co/dbDUpwDZxy

• Direct to Patient Screening for Psoriatic Arthritis in Patients with Psoriasis:…
• https://x.com/RichardPAConway/status/1858602829146960258/photo/1

Sharma @Amansharmapgi et al. DADA2. Clinical manifestations of 101(!) patients. @RheumNow #ACR24 Abstr#2647 https://t.co/Tkk6Rz6rtT https://t.co/frvFPYy4xf

• Clinical Characteristics , Treatment Outcomes and Predictors of Mortality in a …
• https://x.com/RichardPAConway/status/1858603584356774002/photo/1

Evaluation of Bimekizumab in PsA At last year’s ACR, I shared about the early clinical trial data on bimekizumab in psoriatic arthritis. Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17A and F. There have been more updates on the 2… https://t.co/lphZUiiq5T https://t.co/zuHpBaMtEv

Zou et al. Phase 2 RCT Vunakizumab, humanized IL17A in PsA. 12 week study. ACR responses shown in figure, looks similar to existing IL17As. @RheumNow #ACR24 Abstr#2581 https://t.co/Td5xlMYrAd https://t.co/Rl4gkmDFOR

• Vunakizumab in Patients with Active Psoriatic Arthritis: A Multicenter, Randomi…
• https://x.com/RichardPAConway/status/1858572630426874065/photo/1

A#2363 Deodhar Bimekizumab fast time to work: BE MOBILE 1 and 2 - rapid treatment responses with separation from PBO as early as 1-2 weeks after single dose. @RheumNow #ACR24 https://t.co/T81Lzyoy7m

• https://x.com/ericdeinmd/status/1858556716075339953/photo/1

Ahmadzay et al. Real world secukinumab in PsA data in 1202 patients. Smokers/ex-smokers have 30% lower treatment retention. But if they maintain treatment, appear to respond equally well. BMI no effect. @RheumNow #ACR24 Abstr#2350 https://t.co/XVPmEBbRu8 https://t.co/QyJirWRKvq

• Do Smoking and Obesity Impact Secukinumab Treatment Outcomes? Real-world Data f…
• https://x.com/RichardPAConway/status/1858553252964692082/photo/1

In their cohort, Dr. Abarza et al reported a small percentage of pts developing PsA before Pso (8.6%) This group also had faster radiographic progression vs. the Pso before PsA group.....something to consider when evaluating these pts. @rheumnow #ACR24 abs2328 https://t.co/YPcAaKFS2I

• https://x.com/RHEUMarampa/status/1858547480293450040/photo/1

A study investigating weight trends in Psoriatic Arthritis (PsA) and the impact of various medications. Analyzing 1754 patients, it explored multifactorial influences on weight changes Key findings: - Significant weight loss after starting IL17i, IL23i, and csDMARDs. - TNFi &… https://t.co/qOl2ojV9rL https://t.co/Eh2ZNLeKhn

• https://x.com/i/web/status/1858548221381075437
• https://x.com/synovialjoints/status/1858548221381075437/photo/1

A study evaluating the effectiveness of Direct-to-Patient (D2P) screening for psoriatic arthritis (PsA) in psoriasis patients. Key findings: - 30% response rate from 825 patients; 13% screened positive. - 75% of referrals deemed appropriate, with one-third receiving a new PsA… https://t.co/bcQN6KkC8m https://t.co/zogI2PYvtO

• https://x.com/i/web/status/1858544445156962383
• https://x.com/synovialjoints/status/1858544445156962383/photo/1

Low uveitis rates in patients with axial spondyloarthritis and psoriatic arthritis treated with bimekizumab (BKZ) over the long term. Key findings: - AxSpA: 3.7% incidence (1.3/100 PY) with BKZ. - PsA: Only 0.2% incidence (0.1/100 PY). - All events were mild/moderate, with no… https://t.co/jkUwHJk3FJ https://t.co/gTcCzeC88e

• https://x.com/i/web/status/1858536895019438208
• https://x.com/synovialjoints/status/1858536895019438208/photo/1